Stifel Nicolaus analyst Justin Keywood reiterated a Buy rating on NervGen Pharma on May 21 and set a price target of $6.00.Meet Samuel – Your Personal Investing ProphetStart a conversation with TipRanks’ trusted, data-backed investment intelligence
Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, NervGen Pharma, and DRI Healthcare. According to TipRanks, Keywood has an average return of -0.6% and a 52.18% success rate on recommended stocks.
Currently, the analyst consensus on NervGen Pharma is a Strong Buy with an average price target of $11.90.
Based on NervGen Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of C$1.7 million. In comparison, last year the company had a GAAP net loss of C$2.74 million
